Moderna
Prezzo: 49.91Società e modello di business
Moderna is a biotechnology company focused on developing messenger RNA (mRNA) therapeutics and vaccines. Its core products include the COVID-19 vaccine and various candidates for infectious diseases, cancer, and rare diseases. The company primarily generates revenue from vaccine sales, with a significant portion derived from government contracts and partnerships. Moderna's business segments include research and development, manufacturing, and commercialization of its mRNA-based products.
Profilo di investimento
The investment profile of Moderna is more aligned with growth investors, given its focus on innovative mRNA technology and potential future product pipeline. However, the high risk associated with its current financial performance and market volatility may deter conservative investors. The stock may appeal to those with a medium to long-term horizon who are willing to navigate potential fluctuations.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- -8.15 Rischio
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -42.6% ↓
- Sorpresa EPS
- 60.9% meglio del previsto
- Volatilità 20g
- 3.9% stabile
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-11 05:23 | Mantieni | Vendi | scenario_deterioration |
| 2026-06-05 02:43 | Vendi | Mantieni | Weak fundamentals offset by recent price momentum. |
| 2026-06-03 02:47 | Mantieni | Vendi | scenario_deterioration |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-05-04 13:36 | UBS | Target alzato | 36 → 45 | 47.465 |
| 2026-05-04 12:36 | RBC Capital | Target alzato | 35 → 38 | 46.87 |
| 2026-05-01 23:40 | Goldman Sachs | Target alzato | 43 → 49 | 45.37 |
Ancora nulla